Live Breaking News & Updates on Nasdaq Amlx

Stay updated with breaking news from Nasdaq amlx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Brokerages Expect Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) to Post -$0.90 Earnings Per Share

Equities research analysts predict that Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) will post ($0.90) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Amylyx Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.96) and the highest is ($0.84). The business is expected to issue its next […] ....

United States , Amylyx Pharmaceuticals , Amylyx Pharmaceuticals Inc , Zacks Investment Research , Amylyx Pharmaceuticals Get Rating , Get Rating , Amylyx Pharmaceutical , Nasdaq Amlx ,

Citigroup Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) to Buy

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) was upgraded by analysts at Citigroup to a “buy” rating in a note issued to investors on Monday, Stock Target Advisor reports. The firm presently has a $32.00 target price on the stock. Citigroup’s price target suggests a potential upside of 160.80% from the stock’s previous close. NASDAQ:AMLX traded […] ....

United States , Amylyx Pharmaceuticals , Amylyx Pharmaceuticals Inc , Analyst Recommendations For Amylyx Pharmaceuticals , Amylyx Pharmaceuticals Company Profile Get Rating , Get Rating , Stock Target Advisor , Pharmaceuticals Company Profile , Target Advisor , Nasdaq Amlx , Citigroup Inc ,

Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Citigroup

Equities researchers at Citigroup started coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) in a research report issued on Wednesday, Stock Target Advisor reports. The brokerage set a “buy” rating and a $21.00 price target on the stock. Citigroup’s target price would indicate a potential upside of 148.52% from the company’s previous close. […] ....

United States , Amylyx Pharmaceuticals Inc , Analyst Recommendations For Amylyx Pharmaceuticals , Amylyx Pharmaceuticals , Goldman Sachs Group , Amylyx Pharmaceuticals Company Profile Get Rating , Get Rating , Stock Target Advisor , Pharmaceuticals Company Profile , Target Advisor , Nasdaq Amlx , Initiated Coverage , Citigroup Inc ,

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Expected to Post Earnings of -$0.75 Per Share

Equities analysts expect Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) to post ($0.75) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Amylyx Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.81) and the highest estimate coming in at ($0.68). The company is […] ....

United States , Amylyx Pharmaceuticals , Amylyx Pharmaceuticals Inc , Zacks Investment Research , Goldman Sachs Group , Amylyx Pharmaceuticals Get Rating , Get Rating , Amylyx Pharmaceutical , Nasdaq Amlx ,

Zacks: Brokerages Anticipate Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Will Announce Earnings of -$0.75 Per Share

Analysts expect Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) to post ($0.75) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Amylyx Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.68) and the lowest estimate coming in at ($0.81). The business is scheduled to announce its […] ....

United States , Amylyx Pharmaceuticals , Amylyx Pharmaceuticals Inc , Zacks Investment Research , Goldman Sachs Group , Amylyx Pharmaceuticals Get Rating , Get Rating , Amylyx Pharmaceutical , Investment Research , Nasdaq Amlx ,